Trump Plans to Launch TrumpRx Website to Lower Drug Prices
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 12h ago
0mins
Should l Buy GDRX?
President Trump is planning to announce the launch of his TrumpRx website, which uses technology from health care company GoodRx (GDRX), on Thursday night as part of his plan to lower drug prices in the U.S., reported STAT News' Elaine Chen, John Wilkerson, and Chelsea Cirruzzo. The website is expected to display the cash prices for certain drugs and direct patients to other sites where they can buy the therapies, but some experts are skeptical the platform will meaningfully affect affordability, the report noted. Publicly traded large cap drugmakers include AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GDRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GDRX
Wall Street analysts forecast GDRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GDRX is 4.46 USD with a low forecast of 2.60 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
4 Buy
4 Hold
2 Sell
Hold
Current: 2.210
Low
2.60
Averages
4.46
High
7.00
Current: 2.210
Low
2.60
Averages
4.46
High
7.00
About GDRX
GoodRx Holdings, Inc. is a platform for medication savings in the United States, used by consumers and healthcare professionals. The Company connects consumers, healthcare professionals, payers, pharmacy benefit managers (PBMs), pharma manufacturers, and retail pharmacies to make saving on medications easier. The Company's offerings include prescription marketplace and pharma manufacturer solutions. Its prescription marketplace consists of its prescription transactions offering and its supplemental subscription and telehealth offerings. Through its GoodRx Care platform, the Company offers consumers access to telehealth visits on a cash-pay basis outside of insurance. The Company partners with pharma manufacturers to advertise and integrate their affordability solutions into its platform. These solutions, provided by pharma manufacturers, include co-pay cards, patient assistance programs, care portals, and other savings options to ensure consumers can access their medications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Amazon Enters GLP-1 Drug Market, Competing with Pharma Giants
- Intensifying Market Competition: Pharmaceutical giants Eli Lilly and Novo Nordisk are competing in the GLP-1 drug space, particularly as Novo Nordisk is set to regain market share by launching the oral version of Wegovy in 2026, which could shift overall market dynamics.
- Amazon's Market Opportunity: Amazon has begun selling the oral version of Wegovy, with monthly costs as low as $25 for insured customers and $149 for uninsured ones, positioning itself to capture significant retail market share due to its vast customer base and convenient purchasing options.
- Shifting Consumer Preferences: The introduction of oral GLP-1 drugs is expected to encourage more consumers to try these medications for weight loss, driving overall demand and benefiting all companies involved in this sector.
- Impact on Competitive Landscape: Companies like Hims & Hers, WW International, and GoodRx face tough competition, especially as GLP-1 drugs gain popularity; Amazon's 200 million Prime members provide it with a substantial advantage in the e-commerce space, potentially leading to a decline in market share for other competitors.
See More
GoodRx Partners with TrumpRx to Launch Drug Discounts
- Core Partnership: GoodRx has become a key integration partner for TrumpRx, powering pricing for major pharmaceutical companies like Pfizer, covering over 30 essential brand medications, significantly enhancing consumer access to discounts and transparency.
- Significant Discounts Launch: Pfizer is introducing discounts for more than 30 brand medications via GoodRx on TrumpRx, with savings reaching up to 85% and averaging 50%, which will greatly reduce patients' medication costs and promote accessibility.
- Streamlined Operations: GoodRx simplifies the implementation of Most Favored Nation (MFN) pricing policies for manufacturers by unifying pricing, pharmacy enablement, and consumer experience, thereby accelerating patient access to savings and medication.
- Market Impact: GoodRx serves nearly 25 million consumers annually and has helped Americans save over $100 billion on medications, and this partnership will further solidify its leadership in the prescription discount market, driving transformation in the pharmaceutical industry.
See More
GoodRx Partners with TrumpRx to Launch Drug Discounts
- Drug Discount Integration: GoodRx has become a key integration partner for TrumpRx, launching discounted cash prices for over 30 Pfizer brand medications, which is expected to significantly enhance consumer transparency and access to drug pricing, thereby improving healthcare experiences for millions of Americans.
- Significant Savings: Discounts through GoodRx for Pfizer's primary care and select specialty medications reach up to 85%, averaging 50% savings, which not only provides substantial economic support to patients but may also drive market acceptance and usage of these medications.
- Streamlined Operations: GoodRx offers manufacturers a scalable solution to rapidly implement Most Favored Nation (MFN) and other policy-aligned pricing programs, accelerating patient access and drug affordability, further solidifying GoodRx's leadership in the drug pricing sector.
- Digital Storefront Launch: The introduction of GoodRx's Pfizer-branded digital storefront aids consumers in finding new low prices through a simple and trusted entry point, which not only enhances the shopping experience but may also strengthen GoodRx's partnerships with pharmaceutical manufacturers, facilitating the rollout of more discount programs in the future.
See More
GoodRx Achieves HITRUST i1 Certification for Cybersecurity Leadership
- Certification Achievement: GoodRx has earned the 2026 HITRUST i1 Certification, demonstrating its ongoing commitment to safeguarding sensitive healthcare information and reinforcing its leadership in cybersecurity.
- Data Protection Measures: This certification covers GoodRx's AWS-hosted drug savings platform, ensuring robust data protection controls are implemented across data centers in California, Ohio, Oregon, and Virginia, effectively mitigating information risk.
- User Base: GoodRx serves nearly 25 million consumers and over one million healthcare professionals annually, helping users save over $100 billion on medication costs by reducing friction and inefficiencies in the purchasing process, highlighting its critical role in the healthcare ecosystem.
- Strategic Significance: The HITRUST certification not only validates GoodRx's security measures but also reflects its proactive approach to addressing current and emerging threats, enhancing user trust in its platform and further driving the company's market share in the healthcare industry.
See More
Trump's Venezuela Initiative Is Driving Up Oil Stocks: The Raid Was the Simple Step.
Investment Challenges: Convincing U.S. oil companies to invest heavily in a geopolitically unstable country is a significant challenge.
Long-term Price Impact: The goal of such investments would be to potentially lower the long-term price of crude oil.
Trump's Deal-making: The task may be particularly difficult even for President Trump's self-identified skills in deal-making.
Geopolitical Risks: The instability of the target country adds complexity and risk to the investment proposition.
See More
Novo Nordisk Launches Wegovy Pill with 17% Average Weight Loss Efficacy
- Significant Weight Loss Efficacy: The Wegovy pill demonstrates an average weight loss of approximately 17% (16.6%) when combined with a reduced-calorie diet and exercise, compared to only 3% (2.7%) for the placebo, indicating strong market potential that could drive Novo Nordisk's sales growth.
- Diverse Purchasing Channels: Wegovy is available through various outlets, including CVS and Costco, with a starting dose of 1.5 mg priced at around $149 per month, ensuring patient accessibility and expanding market coverage.
- Price Strategy Adjustment: Novo Nordisk has halved Wegovy prices in China ahead of impending generic competition, a strategy that not only enhances market competitiveness but may also attract more consumers to choose its products.
- Stock Performance Recovery: Novo Nordisk shares rose 4.14% to $54.55, although still trading 8.4% below the 200-day SMA, the recent strong performance may attract more investor interest and boost market confidence.
See More
Amazon Enters GLP-1 Drug Market, Competing with Pharma Giants
- Intensifying Market Competition: Pharmaceutical giants Eli Lilly and Novo Nordisk are competing in the GLP-1 drug space, particularly as Novo Nordisk is set to regain market share by launching the oral version of Wegovy in 2026, which could shift overall market dynamics.
- Amazon's Market Opportunity: Amazon has begun selling the oral version of Wegovy, with monthly costs as low as $25 for insured customers and $149 for uninsured ones, positioning itself to capture significant retail market share due to its vast customer base and convenient purchasing options.
- Shifting Consumer Preferences: The introduction of oral GLP-1 drugs is expected to encourage more consumers to try these medications for weight loss, driving overall demand and benefiting all companies involved in this sector.
- Impact on Competitive Landscape: Companies like Hims & Hers, WW International, and GoodRx face tough competition, especially as GLP-1 drugs gain popularity; Amazon's 200 million Prime members provide it with a substantial advantage in the e-commerce space, potentially leading to a decline in market share for other competitors.
See More
GoodRx Partners with TrumpRx to Launch Drug Discounts
- Core Partnership: GoodRx has become a key integration partner for TrumpRx, powering pricing for major pharmaceutical companies like Pfizer, covering over 30 essential brand medications, significantly enhancing consumer access to discounts and transparency.
- Significant Discounts Launch: Pfizer is introducing discounts for more than 30 brand medications via GoodRx on TrumpRx, with savings reaching up to 85% and averaging 50%, which will greatly reduce patients' medication costs and promote accessibility.
- Streamlined Operations: GoodRx simplifies the implementation of Most Favored Nation (MFN) pricing policies for manufacturers by unifying pricing, pharmacy enablement, and consumer experience, thereby accelerating patient access to savings and medication.
- Market Impact: GoodRx serves nearly 25 million consumers annually and has helped Americans save over $100 billion on medications, and this partnership will further solidify its leadership in the prescription discount market, driving transformation in the pharmaceutical industry.
See More
GoodRx Partners with TrumpRx to Launch Drug Discounts
- Drug Discount Integration: GoodRx has become a key integration partner for TrumpRx, launching discounted cash prices for over 30 Pfizer brand medications, which is expected to significantly enhance consumer transparency and access to drug pricing, thereby improving healthcare experiences for millions of Americans.
- Significant Savings: Discounts through GoodRx for Pfizer's primary care and select specialty medications reach up to 85%, averaging 50% savings, which not only provides substantial economic support to patients but may also drive market acceptance and usage of these medications.
- Streamlined Operations: GoodRx offers manufacturers a scalable solution to rapidly implement Most Favored Nation (MFN) and other policy-aligned pricing programs, accelerating patient access and drug affordability, further solidifying GoodRx's leadership in the drug pricing sector.
- Digital Storefront Launch: The introduction of GoodRx's Pfizer-branded digital storefront aids consumers in finding new low prices through a simple and trusted entry point, which not only enhances the shopping experience but may also strengthen GoodRx's partnerships with pharmaceutical manufacturers, facilitating the rollout of more discount programs in the future.
See More
GoodRx Achieves HITRUST i1 Certification for Cybersecurity Leadership
- Certification Achievement: GoodRx has earned the 2026 HITRUST i1 Certification, demonstrating its ongoing commitment to safeguarding sensitive healthcare information and reinforcing its leadership in cybersecurity.
- Data Protection Measures: This certification covers GoodRx's AWS-hosted drug savings platform, ensuring robust data protection controls are implemented across data centers in California, Ohio, Oregon, and Virginia, effectively mitigating information risk.
- User Base: GoodRx serves nearly 25 million consumers and over one million healthcare professionals annually, helping users save over $100 billion on medication costs by reducing friction and inefficiencies in the purchasing process, highlighting its critical role in the healthcare ecosystem.
- Strategic Significance: The HITRUST certification not only validates GoodRx's security measures but also reflects its proactive approach to addressing current and emerging threats, enhancing user trust in its platform and further driving the company's market share in the healthcare industry.
See More
Trump's Venezuela Initiative Is Driving Up Oil Stocks: The Raid Was the Simple Step.
Investment Challenges: Convincing U.S. oil companies to invest heavily in a geopolitically unstable country is a significant challenge.
Long-term Price Impact: The goal of such investments would be to potentially lower the long-term price of crude oil.
Trump's Deal-making: The task may be particularly difficult even for President Trump's self-identified skills in deal-making.
Geopolitical Risks: The instability of the target country adds complexity and risk to the investment proposition.
See More
Novo Nordisk Launches Wegovy Pill with 17% Average Weight Loss Efficacy
- Significant Weight Loss Efficacy: The Wegovy pill demonstrates an average weight loss of approximately 17% (16.6%) when combined with a reduced-calorie diet and exercise, compared to only 3% (2.7%) for the placebo, indicating strong market potential that could drive Novo Nordisk's sales growth.
- Diverse Purchasing Channels: Wegovy is available through various outlets, including CVS and Costco, with a starting dose of 1.5 mg priced at around $149 per month, ensuring patient accessibility and expanding market coverage.
- Price Strategy Adjustment: Novo Nordisk has halved Wegovy prices in China ahead of impending generic competition, a strategy that not only enhances market competitiveness but may also attract more consumers to choose its products.
- Stock Performance Recovery: Novo Nordisk shares rose 4.14% to $54.55, although still trading 8.4% below the 200-day SMA, the recent strong performance may attract more investor interest and boost market confidence.
See More
